The U.S. Army is looking at testing launched effects from a special missions version of the Bombardier Global 6500 bizjet.
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback